Alimera Sciences - ALIM Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.50
  • Forecasted Upside: 108.91%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$3.59
▲ +0.05 (1.41%)

This chart shows the closing price for ALIM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Alimera Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALIM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALIM

Analyst Price Target is $7.50
▲ +108.91% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Alimera Sciences in the last 3 months. The average price target is $7.50, with a high forecast of $10.00 and a low forecast of $5.00. The average price target represents a 108.91% upside from the last price of $3.59.

This chart shows the closing price for ALIM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Alimera Sciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/1/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/29/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/25/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/25/2024Maxim GroupInitiated CoverageBuy$10.00Low
8/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$5.00Low
6/12/2023Alliance Global PartnersUpgradeNeutral ➝ BuyLow
5/19/2023HC WainwrightLower Target$9.00 ➝ $5.00Low
4/3/2023Craig HallumLower Target$18.00 ➝ $8.00Low
4/3/2023HC WainwrightReiterated RatingBuy$9.00Low
2/23/2023HC WainwrightReiterated RatingBuy$9.00Low
11/21/2022Alliance Global PartnersDowngradeBuy ➝ Neutral$11.00 ➝ $4.50Low
7/28/2022HC WainwrightBoost TargetBuy$8.00 ➝ $9.00Low
5/10/2022HC WainwrightLower Target$10.00 ➝ $8.00High
2/25/2022Alliance Global PartnersLower Target$14.50 ➝ $11.00High
2/25/2022HC WainwrightLower TargetBuy$12.00 ➝ $10.00High
10/14/2021HC WainwrightReiterated RatingBuy$12.00Low
8/17/2021Alliance Global PartnersLower TargetBuy$16.50 ➝ $14.50High
8/16/2021HC WainwrightLower TargetBuy$16.00 ➝ $12.00High
4/15/2021Alliance Global PartnersBoost TargetBuy$15.00 ➝ $16.50High
4/15/2021HC WainwrightBoost TargetBuy$14.00 ➝ $16.00High
2/26/2021Alliance Global PartnersBoost TargetBuy$12.00 ➝ $15.00Low
7/16/2020HC WainwrightReiterated RatingBuy$14.00Low
7/10/2020HC WainwrightReiterated RatingBuy$14.00Low
4/14/2020HC WainwrightLower TargetBuy$15.00 ➝ $14.00Low
4/7/2020B. RileyLower TargetBuy$24.00 ➝ $15.00Low
2/25/2020HC WainwrightReiterated RatingBuy$15.00High
12/4/2019HC WainwrightReiterated RatingBuy$15.00High
11/18/2019HC WainwrightReiterated RatingBuy$15.00Low
9/30/2019B. RileySet TargetBuy$30.00Low
9/4/2019HC WainwrightSet TargetBuy$30.00Low
6/21/2019HC WainwrightReiterated RatingBuyMedium
5/28/2019Craig HallumInitiated CoverageBuy ➝ Buy$45.00High
5/2/2019HC WainwrightReiterated RatingBuy$45.00Low
(Data available from 4/24/2019 forward)

News Sentiment Rating

0.54 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/27/2023
  • 4 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/27/2023
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/26/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/26/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/25/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/24/2024
  • 7 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/25/2024
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/24/2024

Current Sentiment

  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Alimera Sciences logo
Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
Read More

Today's Range

Now: $3.59
Low: $3.52
High: $3.63

50 Day Range

MA: $3.71
Low: $3.25
High: $4.21

52 Week Range

Now: $3.59
Low: $1.56
High: $4.38

Volume

16,176 shs

Average Volume

76,619 shs

Market Capitalization

$187.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18

Frequently Asked Questions

What sell-side analysts currently cover shares of Alimera Sciences?

The following Wall Street sell-side analysts have issued reports on Alimera Sciences in the last year: Alliance Global Partners, HC Wainwright, Maxim Group, and StockNews.com.
View the latest analyst ratings for ALIM.

What is the current price target for Alimera Sciences?

2 Wall Street analysts have set twelve-month price targets for Alimera Sciences in the last year. Their average twelve-month price target is $7.50, suggesting a possible upside of 108.9%. Maxim Group has the highest price target set, predicting ALIM will reach $10.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $5.00 for Alimera Sciences in the next year.
View the latest price targets for ALIM.

What is the current consensus analyst rating for Alimera Sciences?

Alimera Sciences currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ALIM will outperform the market and that investors should add to their positions of Alimera Sciences.
View the latest ratings for ALIM.

What other companies compete with Alimera Sciences?

How do I contact Alimera Sciences' investor relations team?

Alimera Sciences' physical mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The biopharmaceutical company's listed phone number is (678) 990-5740 and its investor relations email address is [email protected]. The official website for Alimera Sciences is www.alimerasciences.com. Learn More about contacing Alimera Sciences investor relations.